Multiple Sclerosis

NICE gives Aubagio the nod

The price watchdog said Sanofi's oral MS drug Aubagio is a go. The decision follows a September directive to prove the drug's cost-effectiveness.

Biogen CEO cautions on Tecfidera EU launch

Biogen CEO cautions on Tecfidera EU launch

By

The MS pill saw rapid uptake in the US last year, but its overseas launch won't be as quick, CEO George Scangos conceded this week at an analyst conference.

The year's most popular stories

The year's most popular stories

Our year-end list captures the 10 that sparked heaviest interest.

Lemtrada US rejection snarls Sanofi

Lemtrada US rejection snarls Sanofi

By

The firm has vowed to appeal an FDA rejection that otherwise complicates its bid to expand in multiple sclerosis.

Osbourne joins Teva for "You Don't Know Jack About MS"

Osbourne joins Teva for "You Don't Know Jack About MS"

By

Famous from his reality show, "The Osbournes," Jack narrates his life with MS in a web documentary series.

Teva unclear on 2014 future

The company released two financial scenarios. The key is generic Copaxone.

Panel's Lemtrada endorsement not a rallying call

Panel's Lemtrada endorsement not a rallying call

By

Reviewers supported the drug's approval, but concerns about REMS and clinical trial integrity indicate the vote was not a roaring endorsement.

Small patient majority supports risky Sanofi MS drug: poll

Small patient majority supports risky Sanofi MS drug: poll

By

Most patients would advise today's FDA Lemtrada panel to allow doctors to gauge the drug's risk-benefit profile, although there was strong sentiment on either side of the issue.

Lemtrada's future in doubt after reviewers flag safety issues

Lemtrada's future in doubt after reviewers flag safety issues

By

Safety reviewers' reservations about the MS drug's risk profile, unveiled in briefing documents ahead of an ad-com meeting, suggest it won't be smooth sailing for the drug in the US.

Biogen Idec: Tecfidera not cause of patient's death

The drug maker says a patient's physician did not link the MS drug to her death.

Business briefs: Boehringer Ingelheim, Sanofi, GSK, Teva

BI cancer drug lands breakthrough therapy designation; Sanofi tallies two European MS drug approvals; GSK terminates testing for a Crohn's drug; and Teva joins cancer collaboration

FDA investigating report of PML in a Gilenya patient

By

The FDA and Novartis are investigating reports that a patient has contracted the rare virus.

Business briefs: Novartis, Regeneron and Pfizer

Novartis prepares for a strategic review that hints at scuttling lesser-performing businesses; Regeneron's Eylea sales prompt expansion; Pfizer targets diabetes and obesity; and the FDA approves an MS stem cell trial

Unabated Tecfidera growth propels Biogen

By

Biogen Idec raised its full-year guidance on Tecfidera launch sales, as the MS market continues its growth trajectory.

Business briefs: AbbVie, Teva, HIV, Diabetes, iPhone

AbbVie lays off 100 R&D staff; Teva looks to expand Copaxone footprint; researchers crack HIV protein code; monitors may be misleading diabetics and a prototype sensor turns iPhones into virus hunters.

Biogen reports sales jump, backs tolerability of new MS pill

By

Execs unveiled 10% sales growth and told investors the safety news does not implicate their just-approved MS pill.

Business Briefs: Docs question Gleevec price, Sanofi pill may delay MS onset

Doctors call out Novartis on drug prices; Aubagio shows strong top-line data in trials; and overseas docs increasingly turn to digital.

MS patients hungry for info on orals, says survey

MS patients hungry for info on orals, says survey

By

MS patients have an "insatiable appetite" for information about treatments online, particularly the new class of oral treatments, whose manufacturers could be doing more to prep them for switch conversations, a survey suggests.

Biogen brags of Phase III data for would-be Aubagio rival oral MS drug

By

A study in the New England Journal of Medicine said patients had a significant relapse reduction over two years on the oral drug.

FDA approves Sanofi daily MS pill

By

The move expands patient options, but industry watchers tell MM&M it's not going to spur a radical change in treatment.

Company news: Medivation/Astellas and Teva

A cancer drug being developed by Medivation and Astellas gets its closeup, and Teva launches in to Phase III trials of its oral MS drug laquinimod.

Genzyme-backed program to chronicle lives of patients with MS

Genzyme-backed program to chronicle lives of patients with MS

By

Five patients will document their challenges and triumphs online in this project developed by the National MS Society and Sanofi's Genzyme unit.

Tysabri gets boost from label change, new diagnostic

Tysabri gets boost from label change, new diagnostic

By

Biogen Idec and Elan, which market Tysabri for multiple sclerosis, won approval to add new safety information to the drug's label that could boost sales by helping doctors avoid a serious adverse event.

Email Newsletters